Captor Therapeutics (WAR:CTX) Net Margin %: -3,467.99% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:CTX Captor Therapeutics SA WAR:CTX
38 GF Score
Price zł73.50
GF Value zł10.13
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Captor Therapeutics Net Margin %?

Captor Therapeutics WAR:CTX -2.52% 38 Net Margin % is -3,467.99% as of Mar. 2026. GuruFocus rates WAR:CTX with a GF Score™ of 38/100 and a GF Value™ of zł10.13 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 941 Biotechnology companies, Captor Therapeutics ranks worse than 83.42% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Captor Therapeutics's Net Income for the three months ended in Mar. 2026 was zł-11.38 Mil. Captor Therapeutics's Revenue for the three months ended in Mar. 2026 was zł0.33 Mil. Therefore, Captor Therapeutics's net margin for the quarter that ended in Mar. 2026 was -3,467.99%.

The historical rank and industry rank for Captor Therapeutics's Net Margin % or its related term are showing as below:

WAR:CTX' s Net Margin % Range Over the Past 10 Years
Min: -27637.5   Med: -534.69   Max: -37.97
Current: -1790.64

WAR:CTX's Net Margin % is ranked worse than
83.42% of 941 companies
in the Biotechnology industry
Industry Median: -88.29 vs WAR:CTX: -1790.64

Captor Therapeutics  (WAR:CTX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Captor Therapeutics Net Margin % Related Terms

Captor Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Captor Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Captor Therapeutics Net Margin % Chart

Captor Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only -817.16 -391.94 -534.69 -242.82 -901.22

Captor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -411.32 -485.32 0.00 -22,831.82 -3,467.99

WAR:CTX vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Captor Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Captor Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Captor Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Captor Therapeutics's Net Margin % falls into.


WAR:CTX
38GF Score
Captor Therapeutics SA WAR:CTX
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Captor Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Captor Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-41.997/4.66
=-901.22 %

Captor Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-11.375/0.328
=-3,467.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -3,467.99% mean?
Captor Therapeutics (WAR:CTX) has a Net Margin % of -3,467.99% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Captor Therapeutics and its competitors. According to the industry distribution chart, Captor Therapeutics ranks #785 out of 941 companies in the Biotechnology industry, placing it in the top 83.4%.
Is Captor Therapeutics' Net Margin % too high?
Captor Therapeutics' current Net Margin % is -3,467.99%. Based on the distribution chart, Captor Therapeutics ranks #785 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Captor Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Captor Therapeutics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Captor Therapeutics ranks #785 out of 941 companies for Net Margin %. This places Captor Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Captor Therapeutics and its competitors. Captor Therapeutics's current Net Margin % is -3,467.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Captor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Captor Therapeutics (WAR:CTX) is currently considered Significantly Overvalued. The stock's GF Value™ is zł10.13, compared to a current price of zł73.50 — trading 625.6% above its estimated fair value. The current Net Margin % is -3,467.99%. Captor Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Captor Therapeutics (WAR:CTX), the current Net Margin % is -3,467.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Captor Therapeutics (WAR:CTX) Overvalued in 2026?

Based on GuruFocus' analysis, Captor Therapeutics stock appears to be overvalued. The current stock price of zł73.50 is trading 625.6% above its estimated GF Value™ of zł10.13. GuruFocus considers Captor Therapeutics to be Significantly Overvalued.

Key valuation signals for WAR:CTX:

  • Net Margin %: -3,467.99%
  • GF Value™: zł10.13 vs. price of zł73.50 (625.6% above fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the WAR:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Captor Therapeutics Business Description

Address ul. Dunska 11, Wroclaw, POL, 54-427
Captor Therapeutics SA is a biopharmaceutical company. It is focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.
38GF Score

Get the complete analysis for WAR:CTX

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł73.50
Price
zł10.13
GF Value